United Therapeutics Corp

United Therapeutics insider trades signal a cautious yet optimistic move: CEO and EVP buy at 10‑b‑5‑1 prices, hinting at future growth from upcoming prostacyclin data.

United Therapeutics insider sale: CEO’s 10(b) 5‑1 plan explains the modest 9,500‑share sell‑off—no market‑moving impact, just routine liquidity.

Olian Judy D. sells 200 shares of United Therapeutics Corp. in a planned 10b5‑1 transaction—insider activity that signals routine portfolio rebalancing and long‑term confidence in the company’s pulmonary‑hypertension pipeline.

United Therapeutics’ insider buys signal confidence in its vascular pipeline. Discover how UTX‑001 and other agents could reshape PAH treatment and what safety data show.

Insightful look at United Therapeutics’ insider trades shows disciplined execution, steady growth, and confidence in its oral prostacyclin pipeline—no red flags, just strategic stability.

United Therapeutics insider buying shows leadership confidence—analyzing Benkowitz trades, strategic moves, and market conditions for investors.

Explore United Therapeutics’ insider sale, clinical impact and pipeline – why a 50‑share trade matters to clinicians and investors alike.

United Therapeutics insider activity shows a routine round‑trip option trade that highlights solid governance, a robust pulmonary hypertension pipeline, and steady financials—no red‑flag sign of distress.

Insider buying shows United Therapeutics’ confidence in its PAH pipeline: a disciplined plan‑driven purchase signals long‑term upside for investors.

Insightful analysis of Malcolm Jan’s insider sales at United Therapeutics, showing the routine nature of the 10‑billion‑plan and its minimal impact on a strong PH‑drug company’s valuation.